Free Trial

ImmunityBio (IBRX) Short Interest Ratio & Short Volume

ImmunityBio logo
$2.62 -0.05 (-1.87%)
(As of 12/20/2024 05:45 PM ET)

ImmunityBio Short Interest Data

ImmunityBio (IBRX) has a short interest of 49.78 million shares, representing 31.19% of the float (the number of shares available for trading by the public). This marks a -4.36% decrease in short interest from the previous month. The short interest ratio (days to cover) is 9.8, indicating that it would take 9.8 days of the average trading volume of 5.07 million shares to cover all short positions.

Current Short Interest
49,780,000 shares
Previous Short Interest
52,050,000 shares
Change Vs. Previous Month
-4.36%
Dollar Volume Sold Short
$250.89 million
Short Interest Ratio
9.8 Days to Cover
Last Record Date
November 30, 2024
Outstanding Shares
696,831,000 shares
Float Size
159,580,000 shares
Short Percent of Float
31.19%
Today's Trading Volume
7,861,021 shares
Average Trading Volume
5,066,788 shares
Today's Volume Vs. Average
155%
Short Selling ImmunityBio?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for ImmunityBio and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

IBRX Short Interest Over Time

IBRX Days to Cover Over Time

IBRX Percentage of Float Shorted Over Time

ImmunityBio Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
11/30/202449,780,000 shares $250.89 million -4.4%31.2%9.8 $5.04
11/15/202452,050,000 shares $233.70 million -1.3%32.6%10.3 $4.49
10/31/202452,750,000 shares $274.83 million +2.3%33.1%10.8 $5.21
10/15/202451,580,000 shares $190.85 million -2.1%32.3%18.4 $3.70
9/30/202452,680,000 shares $195.97 million +3.8%33.0%19.2 $3.72
9/15/202450,740,000 shares $181.65 million -1.1%31.8%17.9 $3.58
8/31/202451,290,000 shares $202.60 million +4.3%32.2%16.3 $3.95
8/15/202449,180,000 shares $195.74 million +5.2%31.6%15.2 $3.98
7/31/202446,770,000 shares $240.87 million -3.5%30.3%13.5 $5.15
7/15/202448,480,000 shares $308.33 million -1.2%31.4%7.5 $6.36
6/30/202449,080,000 shares $310.19 million -8.2%31.8%7.2 $6.32
6/15/202453,440,000 shares $318.50 million -0.1%34.6%7.5 $5.96
5/31/202453,470,000 shares $343.28 million +0.1%34.6%7.7 $6.42
5/15/202453,430,000 shares $432.78 million -3.1%38.0%7.2 $8.10
4/30/202455,140,000 shares $440.57 million +0.6%40.1%7.8 $7.99
4/15/202454,840,000 shares $287.36 million +0.1%40.1%11.7 $5.24
3/31/202454,770,000 shares $294.11 million +2.9%41.5%13.6 $5.37
3/15/202453,250,000 shares $273.17 million +3.3%40.4%13.3 $5.13
2/29/202451,550,000 shares $243.83 million +9.4%39.4%12.2 $4.73
2/15/202447,140,000 shares $225.33 million +7.3%36.1%11.4 $4.78
1/31/202443,930,000 shares $147.60 million +4.8%33.6%10.5 $3.36
1/15/202441,930,000 shares $161.43 million +3.5%32.1%6.8 $3.85
12/31/202340,520,000 shares $203.41 million +7.1%31.0%6.8 $5.02
12/15/202337,840,000 shares $162.71 million +4.7%N/A6.5 $4.30
11/30/202336,140,000 shares $133.00 million +1.4%N/A6.6 $3.68
11/15/202335,660,000 shares $145.85 million -14.9%N/A6.7 $4.09
10/31/202341,920,000 shares $131.63 million +0.7%N/A8.7 $3.14
10/15/202341,640,000 shares $54.55 million +5.3%N/A13.7 $1.31
9/30/202339,540,000 shares $66.82 million +8.5%30.2%14.6 $1.69
9/15/202336,440,000 shares $65.59 million +36.4%19.8%14.1 $1.80
8/31/202326,720,000 shares $43.02 million +17.4%23.5%10.7 $1.61
8/15/202322,760,000 shares $44.61 million -4.8%20.0%8.8 $1.96
7/31/202323,900,000 shares $52.58 million -0.8%22.0%6.1 $2.20
7/15/202324,100,000 shares $67.00 million +3.5%22.2%5.3 $2.78
6/30/202323,290,000 shares $64.75 million -0.6%21.5%4.8 $2.78
6/15/202323,440,000 shares $65.40 million +4.7%21.6%4.6 $2.79
5/31/202322,390,000 shares $61.57 million -10.3%20.7%3.8 $2.75
5/15/202324,960,000 shares $80.37 million -16.7%23.0%4.2 $3.22
4/30/202329,980,000 shares $83.94 million +12.6%27.6%6 $2.80
4/15/202326,630,000 shares $51.40 million -0.4%24.6%6.7 $1.93
WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW
3/31/202326,730,000 shares $48.65 million +4.7%30.7%7.7 $1.82
3/15/202325,520,000 shares $36.49 million +11.7%29.3%8.1 $1.43
2/28/202322,850,000 shares $55.75 million -3.8%26.2%10.1 $2.44
2/15/202323,760,000 shares $83.16 million -1.1%29.0%12.3 $3.50
1/31/202324,030,000 shares $91.31 million +6.2%29.3%14 $3.80
1/15/202322,630,000 shares $108.17 million +0.9%27.6%14.1 $4.78
12/30/202222,430,000 shares $113.72 million -5.5%30.1%14.5 $5.07
12/15/202223,730,000 shares $159.23 million -0.4%31.8%15.8 $6.71
11/30/202223,830,000 shares $131.30 million -1.0%28.8%13.3 $5.51
11/15/202224,080,000 shares $145.68 million +1.5%29.1%14 $6.05
10/31/202223,730,000 shares $130.52 million +1.0%28.6%14.6 $5.50
10/15/202223,490,000 shares $116.04 million -5.0%28.4%14.6 $4.94
9/30/202224,720,000 shares $122.86 million +13.6%29.8%15.6 $4.97
9/15/202221,770,000 shares $139.98 million +7.8%26.3%13.5 $6.43
8/31/202220,190,000 shares $80.76 million +6.5%24.9%13.6 $4.00
8/15/202218,950,000 shares $89.63 million +1.5%23.4%11.1 $4.73
7/31/202218,680,000 shares $72.67 million +1.2%23.2%9.7 $3.89
7/15/202218,460,000 shares $83.07 million -0.4%22.9%9.2 $4.50
6/30/202218,530,000 shares $68.93 million -3.8%23.0%9 $3.72
6/15/202219,270,000 shares $61.86 million +4.3%23.9%9.6 $3.21
5/31/202218,470,000 shares $69.45 million +8.8%23.0%10.9 $3.76
5/15/202216,980,000 shares $59.26 million -1.5%21.1%11 $3.49
4/30/202217,230,000 shares $62.54 million +4.4%21.4%11.7 $3.63
4/15/202216,500,000 shares $83.33 million +3.6%20.5%11.2 $5.05
3/31/202215,930,000 shares $89.37 million -4.4%N/A10.7 $5.61
3/15/202216,670,000 shares $89.52 million +2.0%20.7%9.9 $5.37
2/28/202216,350,000 shares $111.83 million +12.2%20.3%9.6 $6.84
2/15/202214,570,000 shares $102.43 million +12.2%18.1%7.8 $7.03
1/31/202212,990,000 shares $75.60 million +4.6%16.2%7.6 $5.82
1/15/202212,420,000 shares $82.84 million +0.9%N/A7.7 $6.67
12/31/202112,310,000 shares $74.84 million +18.0%15.3%8.3 $6.08
12/15/202110,430,000 shares $59.45 million +9.4%13.0%8.3 $5.70
11/30/20219,530,000 shares $74.24 million +4.7%12.7%8.4 $7.79
11/15/20219,100,000 shares $64.97 million +2.6%12.1%9.4 $7.14
10/29/20218,870,000 shares $69.45 million -3.7%12.0%9.7 $7.83
10/15/20219,210,000 shares $85.65 million -5.3%12.4%10.5 $9.30
9/30/20219,730,000 shares $94.77 million +3.3%13.1%11.4 $9.74
9/15/20219,420,000 shares $90.15 million +2.2%12.7%10 $9.57
8/31/20219,220,000 shares $104.92 million -4.2%13.5%8.6 $11.38
8/13/20219,620,000 shares $108.23 million No Change14.2%8.9 $11.25

IBRX Short Interest - Frequently Asked Questions

What is ImmunityBio's current short interest?

Short interest is the volume of ImmunityBio shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 49,780,000 shares of IBRX short. 31.19% of ImmunityBio's shares are currently sold short. Learn More on ImmunityBio's current short interest.

What is a good short interest ratio for ImmunityBio?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IBRX shares currently have a short interest ratio of 10.0. Learn More on ImmunityBio's short interest ratio.

Which institutional investors are shorting ImmunityBio?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ImmunityBio: National Bank of Canada FI, Jane Street Group LLC, Walleye Capital LLC, LMR Partners LLP, and Mirae Asset Securities USA Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for ImmunityBio?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 31.19% of ImmunityBio's floating shares are currently sold short.

Is ImmunityBio's short interest increasing or decreasing?

ImmunityBio saw a decrease in short interest in November. As of November 30th, there was short interest totaling 49,780,000 shares, a decrease of 4.4% from the previous total of 52,050,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is ImmunityBio's float size?

ImmunityBio currently has issued a total of 696,831,000 shares. Some of ImmunityBio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ImmunityBio currently has a public float of 159,580,000 shares.

How does ImmunityBio's short interest compare to its competitors?

31.19% of ImmunityBio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ImmunityBio: Ascendis Pharma A/S (6.22%), Revolution Medicines, Inc. (9.61%), Lantheus Holdings, Inc. (6.73%), Legend Biotech Co. (13.04%), Nuvalent, Inc. (12.26%), Blueprint Medicines Co. (6.60%), Elanco Animal Health Incorporated (3.15%), Cytokinetics, Incorporated (12.35%), Viking Therapeutics, Inc. (16.22%), TG Therapeutics, Inc. (20.71%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks.

What does it mean to sell short ImmunityBio stock?

Short selling IBRX is an investing strategy that aims to generate trading profit from ImmunityBio as its price is falling. IBRX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against ImmunityBio?

A short squeeze for ImmunityBio occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IBRX, which in turn drives the price of the stock up even further.

How often is ImmunityBio's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IBRX, twice per month. The most recent reporting period available is November, 30 2024.




This page (NASDAQ:IBRX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners